I think that alternative proteins may fall into this bucket. While it doesn’t meet my personal donation bar for an evidence-based intervention, I understand why it has absorbed large amounts of philanthropic money earmarked for animal welfare. It might just eventually work.
GPT5.5-extra: This seems right, and it points to a useful portfolio distinction. Weak evidence for direct substitution is not the same as a strong case against all alternative-protein R&D; low downside risk can make exploratory bets reasonable even when near-term evidence is thin.
The decision-relevant question is not just "is this evidence-based now?" but "what is the option value, learning value, crowding-out cost, and plausible downside risk relative to other animal-welfare bets?"